TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15536472

Group type: EXPERIMENTAL
Intervention: 600 mg soybean‐derived pinitol, twice daily for 13 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 12488371

Group type: COMPARATOR
Intervention: Standard Macintosh laryngoscope
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Five single-use laryngoscopes
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Four single-use laryngoscopes
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: All laryngoscopes tested
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Reusable Macintosh laryngoscope
Number of subjects: 20
Study: 11531789

Group type: EXPERIMENTAL
Intervention: Ointment (O)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Cream (C)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Solution (S)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Low-viscosity cream (LVC)
Number of subjects: 29
Study: 9257795

Group type: EXPERIMENTAL
Intervention: rhuMAb‐E25 (0.15 mg/kg subcutaneously, 0.15 mg/kg intravenously, or 0.5 mg/kg intravenously)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo (subcutaneous and intravenous)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: rhuMAb‐E25
Number of subjects: 240
Study: 8501148

Group type: EXPERIMENTAL
Intervention: GnRH agonist plus estrogen-progestin add-back regimen
Number of subjects: 51

Group type: COMPARATOR
Intervention: GnRH agonist plus progestin add-back regimen
Number of subjects: 51
Study: 3327939

Group type: EXPERIMENTAL
Intervention: Prophylactic treatment with protein-free artificial surfactant (ALEC)
Number of subjects: 0
Study: 31994022

Group type: EXPERIMENTAL
Intervention: ACT‐709478 30 mg once daily for 12 days
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: ACT‐709478 10 mg once daily for 12 days
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: ACT‐709478 10, 30, and 60 mg for 7 days each, then 100 mg once daily for 8 days
Number of subjects: 46

Group type: COMPARATOR
Intervention: ACT‐709478 60 mg and 100 mg with midazolam
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: ACT‐709478
Number of subjects: 46
Study: 30574771

Group type: EXPERIMENTAL
Intervention: Combined sea salt-based oral rinse with xylitol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sea salt
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Xylitol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lysozyme
Number of subjects: 0
Study: 27501724

Group type: EXPERIMENTAL
Intervention: Vegethon mobile app intervention
Number of subjects: 17
Study: 26385664

Group type: EXPERIMENTAL
Intervention: Xenon anaesthesia (50-60 vol%)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Sevoflurane anaesthesia (1.1-1.4 vol%)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Sevoflurane anaesthesia
Number of subjects: 42
Study: 23881846

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 2305

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 2305

Group type: EXPERIMENTAL
Intervention: Warfarin with major hemorrhage included
Number of subjects: 2305

Group type: COMPARATOR
Intervention: Aspirin with major hemorrhage included
Number of subjects: 2305
Study: 20797382

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine (100 or 200 mg/d)
Number of subjects: 387

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 387

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine
Number of subjects: 387
Study: 18592146

Group type: EXPERIMENTAL
Intervention: Corticosteroids (methylprednisolone 40 mg/day)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (600 mg/day)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Basal treatment (regular ipratropium bromide and beta‐2 agonist as needed) + placebo CS + placebo NAC
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Basal treatment + placebo CS + N-acetylcysteine (600 mg/day)
Number of subjects: 58
Study: 16365178

Group type: EXPERIMENTAL
Intervention: Thalidomide plus dexamethasone
Number of subjects: 207

Group type: COMPARATOR
Intervention: Dexamethasone alone
Number of subjects: 207
Study: 14584228

Group type: EXPERIMENTAL
Intervention: Medication review and discharge counselling (Intervention group)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 216
Study: 10922430

Group type: EXPERIMENTAL
Intervention: Double bolus reteplase (10 + 10 U)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Front-loaded alteplase (up to 100 mg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (30 healthy persons)
Number of subjects: 50
Study: 8757514

Group type: EXPERIMENTAL
Intervention: DAT 3 + 10 (daunorubicin for 3 days, cytarabine and 6‐thioguanine for 10 days)
Number of subjects: 972

Group type: EXPERIMENTAL
Intervention: MAZE (m‐AMSA, 5‐azacytidine, etoposide)
Number of subjects: 972

Group type: COMPARATOR
Intervention: COAP (cyclophosphamide, vincristine, cytarabine, prednisone)
Number of subjects: 972

Group type: EXPERIMENTAL
Intervention: 1 year of outpatient maintenance treatment
Number of subjects: 972

Group type: COMPARATOR
Intervention: DAT 1 + 5 (daunorubicin for 1 day, cytarabine and 6‐thioguanine for 5 days)
Number of subjects: 972
Study: 31757197

Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 28

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 28
Study: 30902918

Group type: EXPERIMENTAL
Intervention: Anlotinib (12 mg once daily, 2 weeks on/1 week off)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Sunitinib (50 mg once daily, 4 weeks on/2 weeks off)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Anlotinib
Number of subjects: 133

Group type: COMPARATOR
Intervention: Sunitinib
Number of subjects: 133
Study: 30471800

Group type: EXPERIMENTAL
Intervention: Mouth Care Without a Battle (MCWB) protocol training for NH staff for 2 years
Number of subjects: 219
Study: 26169349

Group type: EXPERIMENTAL
Intervention: Text messaging intervention (3 times a week for 12 weeks)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no text messages)
Number of subjects: 80
Study: 24583275

Group type: EXPERIMENTAL
Intervention: Gambling involvement (gamblers)
Number of subjects: 427

Group type: EXPERIMENTAL
Intervention: High impulsivity gamblers
Number of subjects: 427

Group type: EXPERIMENTAL
Intervention: Male gamblers
Number of subjects: 427

Group type: COMPARATOR
Intervention: Non-gamblers
Number of subjects: 427
Study: 21945145

Group type: EXPERIMENTAL
Intervention: Groshong Catheter
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: PI Catheter
Number of subjects: 26
Study: 18448745

Group type: EXPERIMENTAL
Intervention: CDB-2914 10 mg daily (T1)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: CDB-2914 20 mg daily (T2)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (PLC)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: CDB-2914
Number of subjects: 22
Study: 17217710

Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil 20 mg
Number of subjects: 287

Group type: COMPARATOR
Intervention: Losartan potassium 50 mg
Number of subjects: 287
Study: 12559539

Group type: EXPERIMENTAL
Intervention: Growth hormone (0.03 U/kg per day)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Growth hormone
Number of subjects: 19
Study: 10968443

Group type: EXPERIMENTAL
Intervention: Increased body mass index (BMI) during the first year of life
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increased growth in length in the next 2 years
Number of subjects: 0
Study: 9349571

Group type: EXPERIMENTAL
Intervention: Levothyroxine (LT4) 200 microg daily for 12 months
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control group (no therapy)
Number of subjects: 101
Study: 8349327

Group type: EXPERIMENTAL
Intervention: Losartan (100 mg)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 2878812

Group type: EXPERIMENTAL
Intervention: Diphenhydramine (DPH) 50 mg b.d.
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Temelastine (SKF) 100 mg b.d.
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Diazepam (DZ) 0.3 mg/kg
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 29186976

Group type: EXPERIMENTAL
Intervention: Heated sterile water
Number of subjects: 50

Group type: COMPARATOR
Intervention: ResoClear® impregnation wipes
Number of subjects: 50
Study: 26964731

Group type: EXPERIMENTAL
Intervention: Teriparatide 20 μg sc daily
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg sc every 6 months
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Combination of Teriparatide and Denosumab
Number of subjects: 94
Study: 24491076

Group type: EXPERIMENTAL
Intervention: Alcohol-only intervention
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Combined alcohol and alcohol-related RSB intervention
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Alcohol-related RSB-only intervention
Number of subjects: 480

Group type: COMPARATOR
Intervention: Control
Number of subjects: 480
Study: 22437412

Group type: EXPERIMENTAL
Intervention: Angiotensin receptor blockers (ARBs)
Number of subjects: 1177

Group type: COMPARATOR
Intervention: Non-renin-angiotensin-aldosterone system (non-RAASi)-based therapy
Number of subjects: 1177
Study: 20735818

Group type: EXPERIMENTAL
Intervention: Alcohol-based hand disinfectants
Number of subjects: 1230
Study: 18495838

Group type: EXPERIMENTAL
Intervention: IG water and ID saline
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: ID glucose
Number of subjects: 8

Group type: COMPARATOR
Intervention: IG water and ID glucose
Number of subjects: 8
Study: 17302259

Group type: EXPERIMENTAL
Intervention: Lamivudine therapy for 6-12 months
Number of subjects: 85
Study: 14633287

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 10750762

Group type: EXPERIMENTAL
Intervention: Off-pump coronary bypass graft operation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cardiopulmonary bypass (CPB)
Number of subjects: 0
Study: 8888166

Group type: EXPERIMENTAL
Intervention: Dry mopping with topical and systemic antibiotics and topical steroids
Number of subjects: 524

Group type: EXPERIMENTAL
Intervention: Dry mopping alone
Number of subjects: 524

Group type: COMPARATOR
Intervention: No specific treatment (control)
Number of subjects: 524

Group type: EXPERIMENTAL
Intervention: Children with no otorrhoea
Number of subjects: 524

Group type: EXPERIMENTAL
Intervention: Children with healed ears
Number of subjects: 524
Study: 1410148

Group type: EXPERIMENTAL
Intervention: Abrupt discontinuation of 6 nights of 0.50 mg triazolam
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Tapered discontinuation (3 nights of 0.50 mg, 2 nights of 0.25 mg, and 1 night of 0.125 mg triazolam)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo (6 nights)
Number of subjects: 21
Study: 3873784

Group type: EXPERIMENTAL
Intervention: SPECT (Tomographic 201‐Tl scintigrams)
Number of subjects: 100

Group type: COMPARATOR
Intervention: PLAN (Conventional planar images)
Number of subjects: 100
Study: 30951920

Group type: EXPERIMENTAL
Intervention: Laparoscopic closure of the vaginal cuff after TLH
Number of subjects: 182

Group type: COMPARATOR
Intervention: Transvaginal closure of the vaginal cuff after TLH
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Preoperative FSFI score <26.55
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Bilateral adnexectomy before menopause
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Postoperative vaginal cuff hematoma
Number of subjects: 182
Study: 29078018

Group type: EXPERIMENTAL
Intervention: Cervical mucus removal
Number of subjects: 714

Group type: COMPARATOR
Intervention: Non-mucus removal
Number of subjects: 714
Study: 26323809

Group type: EXPERIMENTAL
Intervention: PI-based second-line ART
Number of subjects: 1251
Study: 26373226

Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate mouthwash (0.2%)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Cinnamon extract
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo (distilled water)
Number of subjects: 105
Study: 23390923

Group type: EXPERIMENTAL
Intervention: Endovascular therapy
Number of subjects: 656

Group type: COMPARATOR
Intervention: Intravenous t-PA alone
Number of subjects: 656
Study: 21916925

Group type: EXPERIMENTAL
Intervention: MI + DVD
Number of subjects: 1021

Group type: COMPARATOR
Intervention: DVD-only
Number of subjects: 1021
Study: 19000581

Group type: EXPERIMENTAL
Intervention: recombinant birch pollen allergen vaccine (rBet v 1)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: natural purified birch pollen allergen (nBet v 1)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: licensed birch pollen extract
Number of subjects: 134
Study: 17200587

Group type: EXPERIMENTAL
Intervention: Phacoemulsification surgery
Number of subjects: 0
Study: 12875064

Group type: EXPERIMENTAL
Intervention: Kidney-tonifying prescription and routine western drugs
Number of subjects: 45

Group type: COMPARATOR
Intervention: Routine western drugs
Number of subjects: 45
Study: 11794070

Group type: EXPERIMENTAL
Intervention: WHO formula vaccines
Number of subjects: 3

Group type: COMPARATOR
Intervention: FDA formula vaccines
Number of subjects: 3
Study: 9124058

Group type: EXPERIMENTAL
Intervention: Oral challenge test with boiled egg and freeze-dried egg white
Number of subjects: 1

Group type: COMPARATOR
Intervention: Double-blind, placebo-controlled food challenge using freeze-dried egg white
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: 20 min patch test with raw egg white
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: 20 min patch test with freeze-dried egg white
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: RAST inhibition assays
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: IgE antibody titers to egg white components
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: IgE antibody titers for ovomucoid fragments digested by pepsin, chymotrypsin, and trypsin
Number of subjects: 1
Study: 8238680

Group type: EXPERIMENTAL
Intervention: Home visitation with husband participation
Number of subjects: 527

Group type: COMPARATOR
Intervention: Home visitation without husband participation (control)
Number of subjects: 527
Study: 3484552

Group type: EXPERIMENTAL
Intervention: High intensity TENS to appropriate acupuncture points
Number of subjects: 45

Group type: COMPARATOR
Intervention: High intensity TENS to inappropriate (placebo) acupuncture points
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study: 30504728

Group type: EXPERIMENTAL
Intervention: Bilateral custom-made AFO plus walking shoes
Number of subjects: 44

Group type: COMPARATOR
Intervention: Walking shoes alone (Control Group)
Number of subjects: 44
Study: 27873388

Group type: EXPERIMENTAL
Intervention: Sildenafil 60 mg three times a day
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 25421976

Group type: EXPERIMENTAL
Intervention: Dietary nitrate (250 mL daily, as beetroot juice)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo (250 mL daily, as nitrate-free beetroot juice)
Number of subjects: 68
Study: 24350416

Group type: EXPERIMENTAL
Intervention: Benzydamine hydrochloride (3 ml, 4.5 mg) dripped on ETT cuff
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 86
Study: 21279863

Group type: EXPERIMENTAL
Intervention: Cold water immersion (14 ± 1 °C)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Tepid water immersion (28 ± 1 °C)
Number of subjects: 14
Study: 19038563

Group type: EXPERIMENTAL
Intervention: Laronidase 0.58 mg/kg once-weekly intravenous infusion
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Laronidase 1.2 mg/kg every 2 weeks
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Laronidase 1.2 mg/kg every week
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Laronidase 1.8 mg/kg every 2 weeks
Number of subjects: 33

Group type: COMPARATOR
Intervention: All dose regimens
Number of subjects: 33
Study: 16908343

Group type: EXPERIMENTAL
Intervention: 800 nm-wavelength diode laser
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1064 nm-wavelength neodymium:yttrium-aluminum-garnet laser
Number of subjects: 0
Study: 14962687

Group type: EXPERIMENTAL
Intervention: Soy milk
Number of subjects: 60

Group type: COMPARATOR
Intervention: Non-fat cow milk
Number of subjects: 60
Study: 11944733

Group type: EXPERIMENTAL
Intervention: Orthosiphon grandiflorus (OG) tea, 2 cups daily (2.5 g dry wt per tea bag)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Sodium potassium citrate (SPC), 5-10 g in solution divided into three times a day
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Combined treatment groups (G1 and G2)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Sodium potassium citrate (SPC)
Number of subjects: 48
Study: 9598253

Group type: EXPERIMENTAL
Intervention: Nitric oxide inhalation (5 and 10 ppm for two hours)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Prone positioning (PP)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Prone positioning + Almitrine (16 mg.kg-1.min-1)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Nitric oxide + Almitrine
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Nitric oxide + Prone positioning
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Nitric oxide + Prone positioning + Almitrine
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control (no further inhalation after initial NO)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Prone positioning
Number of subjects: 27
Study: 7931927

Group type: EXPERIMENTAL
Intervention: School-based intervention with multi-media prompts
Number of subjects: 0

Group type: COMPARATOR
Intervention: Multi-media intervention without prompts
Number of subjects: 0
Study: 3280493

Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment
Number of subjects: 260

Group type: COMPARATOR
Intervention: No antihypertensive treatment (Control)
Number of subjects: 260

Group type: COMPARATOR
Intervention: General population (Control)
Number of subjects: 260
Study: 29570044

Group type: EXPERIMENTAL
Intervention: Intravenous alteplase standard dose of 0.9 mg/kg, up to a maximum of 90 mg, plus oral aspirin placebo
Number of subjects: 948

Group type: COMPARATOR
Intervention: Intravenous alteplase placebo plus active oral aspirin dose of 325 mg
Number of subjects: 948
Study: 27177263

Group type: EXPERIMENTAL
Intervention: Convective warming with an underbody blanket
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conductive warming with an underbody mattress and additional warming of the legs
Number of subjects: 60
Study: 25741816

Group type: EXPERIMENTAL
Intervention: Ocriplasmin 125 μg
Number of subjects: 652

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 652
Study: 24002278

Group type: EXPERIMENTAL
Intervention: FDC-based strategy (n=1002) containing either (1) 75 mg aspirin, 40 mg simvastatin, 10 mg lisinopril, and 50 mg atenolol or (2) 75 mg aspirin, 40 mg simvastatin, 10 mg lisinopril, and 12.5 mg hydrochlorothiazide
Number of subjects: 2004

Group type: COMPARATOR
Intervention: Usual care (n=1002)
Number of subjects: 2004
Study: 21558462

Group type: EXPERIMENTAL
Intervention: Progesterone (90 mg vaginally) from 24 to 34 weeks of pregnancy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo from 24 to 34 weeks of pregnancy
Number of subjects: 0
Study: 18499565

Group type: EXPERIMENTAL
Intervention: Combination-facilitated PCI (abciximab plus half-dose reteplase)
Number of subjects: 2452

Group type: EXPERIMENTAL
Intervention: Abciximab-facilitated PCI
Number of subjects: 2452

Group type: EXPERIMENTAL
Intervention: Primary PCI (abciximab administered immediately before the procedure)
Number of subjects: 2452

Group type: EXPERIMENTAL
Intervention: Combination-facilitated PCI
Number of subjects: 2452

Group type: EXPERIMENTAL
Intervention: Primary PCI
Number of subjects: 2452
Study: 16575661

Group type: EXPERIMENTAL
Intervention: Immediate defect coverage with a pedicled muscle flap (group A)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Vacuum-assisted closure (V.A.C.)-therapy (group B)
Number of subjects: 16
Study: 12675460

Group type: EXPERIMENTAL
Intervention: Sof‐Lex disks
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Diamond paste
Number of subjects: 40

Group type: COMPARATOR
Intervention: White silicon and black rubber
Number of subjects: 40

Group type: COMPARATOR
Intervention: Shofu rubbers
Number of subjects: 40

Group type: COMPARATOR
Intervention: Diamond burs
Number of subjects: 40
Study: 10759437

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 8931286

Group type: EXPERIMENTAL
Intervention: Continuously ventilated hood system
Number of subjects: 5

Group type: COMPARATOR
Intervention: Demand valve system with oral-nasal mask
Number of subjects: 5
Study: 1304176

Group type: EXPERIMENTAL
Intervention: KCl/MFP dentifrice
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo dentifrice
Number of subjects: 41
Study: 30614406

Group type: EXPERIMENTAL
Intervention: 8-week resistance training programme
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (daily routines)
Number of subjects: 30
Study: 28917549

Group type: EXPERIMENTAL
Intervention: Written, verbally performed, preintubation checklist
Number of subjects: 262

Group type: COMPARATOR
Intervention: Usual care (no preintubation checklist)
Number of subjects: 262
Study: 27456910

Group type: EXPERIMENTAL
Intervention: Speed endurance exercise (S)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Speed endurance followed by endurance exercise (S + E)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Endurance exercise (E)
Number of subjects: 17
Study: 24684977

Group type: EXPERIMENTAL
Intervention: Sleep medication (melatonin 14%, clonidine 9%)
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Sleep medication use
Number of subjects: 257
Study: 19959684

Group type: EXPERIMENTAL
Intervention: Continued drinking (average of 2.3 drinks/d) postdiagnosis
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Continued smoking postdiagnosis
Number of subjects: 264

Group type: COMPARATOR
Intervention: Smoking history before diagnosis
Number of subjects: 264

Group type: COMPARATOR
Intervention: Alcohol history before diagnosis
Number of subjects: 264
Study: 15793183

Group type: EXPERIMENTAL
Intervention: Rosiglitazone (4 mg, twice daily)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 11778759

Group type: EXPERIMENTAL
Intervention: Independent review committee (RC 1) evaluation
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Independent review committee (RC 2) evaluation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Local investigator reports
Number of subjects: 60